Sugi Predict

Sugi Predict / Compounds / SCHEMBL1019092

SCHEMBL1019092

SCHEMBL1019092

CC(C)(C)OC(=O)c1ccc(CO)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ ADRB2 P07550 1/20 0.49
▸ ADRB1 P08588 1/20 0.49
▸ ADRB3 P13945 1/20 0.49
▸ PPARG P37231 1/20 0.47
▸ PPARA Q07869 1/20 0.47
▸ EPHX2 P34913 1/20 0.46
▸ HPGD P15428 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ GPR119 Q8TDV5 1/20 0.44
▸ CYP4A11 Q02928 3/20 0.43
▸ PKM P14618 1/20 0.43
▸ SLC7A5 Q01650 1/20 0.43
▸ SIRT2 Q8IXJ6 1/20 0.43
▸ SIRT1 Q96EB6 1/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31047974 0.95 CA12 (0.58) CA1CA2CA12CA9CA14
SCHEMBL7708759 0.86 KMT2A (0.52) CA1CA2CA12CA9CA14
SCHEMBL7588248 0.86 ALDH1A1 (0.55) CA1CA2CA12CA9CA14
SCHEMBL109451 0.85 CA1 (0.61) CA1CA2CA12CA9CA14
SCHEMBL2207588 0.85 CYP4A11 (0.60) CA1CA2CA12CA9CA14
SCHEMBL16617577 0.85 CA1 (0.50) CA1CA2CA12CA9CA14
SCHEMBL7385067 0.85 CA1 (0.50) CA1CA2CA12CA9CA14
SCHEMBL22995926 0.83 PPARG (0.41) CA1CA2CA12CA9CA14
SCHEMBL7588242 0.83 CA1 (0.49) CA1CA2CA12CA9CA14
SCHEMBL18182636 0.83 THRA (0.54) CA1CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020049316-A1 Protease inhibitors HALBERT STACIE MARIE (US) 2002-04-25 — — US claimed
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 — — US disclosed
EP-4629984-A1 DEVELOPMENT OF POTENT DUAL HDAC/BRD4 INHIBITORS BioVentures, LLC (US) 2025-10-15 — — EP disclosed
CN-118239926-A TLR7 and 8 inhibitors, preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 — — CN disclosed
WO-2024123929-A1 DEVELOPMENT OF POTENT DUAL HDAC/BRD4 INHIBITORS BIOVENTURES, LLC (US) 2024-06-13 — — WO disclosed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 — — US disclosed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 — — US disclosed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 — — US disclosed
CN-116390919-A Aromatic compound, preparation method and application thereof 杭州多域生物技术有限公司 2023-07-04 — — CN disclosed
EP-3596067-B1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2023-06-07 — — EP disclosed
US-20020049316-A1 Protease inhibitors HALBERT STACIE MARIE (US) 2002-04-25 — — US disclosed
US-6159973-A Aromatic amides, their preparation process, the compositions containing them and their use as pesticides HOECHST SCHERING AGREVO S.A. (FR) 2000-12-12 — — US disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 — — EP disclosed
EP-1019046-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-07-19 — — EP disclosed
US-6013837-A E.G.,4-(2-(3,4,5-TRICHLORO PHENYL) 1-FLUOROCYCLOPROPYL)-N-(2-METHYL PHENYL)BENZAMIDE; PARTICULAR USE AGAINST ARTHROPODS, HELMINTHS AND MOLLUSCS; INSECTICIDES; ACARICIDES; NEMATICIDES; PHOTOSTABILITY; NONTOXIC TO MAMMALS HOECHST MARION ROUSSEL (FR) 2000-01-11 — — US disclosed
WO-1998048799-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 — — WO disclosed
US-5614555-A Amidinophenol derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1997-03-25 — — US disclosed
EP-0588655-B1 Amidinophenol derivatives ONO PHARMACEUTICAL CO (JP) 1996-12-04 — — EP disclosed
US-5432178-A Substituted benzoic acid esters; use to prevent or treat inflammatory diseases, allergic diseases, disseminated intravascular coagulation, pancreatitis or multiple organ failure ONO PHARMACEUTICAL CO., LTD. (JP) 1995-07-11 — — US disclosed
EP-0588655-A1 Amidinophenol derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1994-03-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049316-A1 Protease inhibitors CTSK, CTSZ, CTSG CA1 261/4885CA2 133/4885CA12 746/4885
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC5, ABCC1 CA1 4868/4885CA2 3390/4885CA12 4745/4885
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC1 CA1 4868/4885CA2 3390/4885CA12 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback